<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04270578</url>
  </required_header>
  <id_info>
    <org_study_id>218/2012BO2</org_study_id>
    <nct_id>NCT04270578</nct_id>
  </id_info>
  <brief_title>Gestational Diabetes</brief_title>
  <acronym>PREG</acronym>
  <official_title>German Study Gestational Diabetes (PREG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deutsches Diabeteszentrum (DDZ), Leibniz-Institut Düsseldorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl Gustav Carus, TU Dresden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Klinik für Diabetologie an der Medizinischen Klinik - Innenstadt, LMU München</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitätsklinik Heidelberg, Abteilung Innere Medizin I, Schwerpunkt Endokrinologie und Stoffwechsel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitätsklinikum Leipzig, IFB Adipositas Erkrankungen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Due to a changed lifestyle with less physical activity, unfavorable diets rich in fat and
      calories and obesity, the prevalence of diabetes mellitus is increasing worldwide. The
      diabetes epidemic is associated with significant personal and socio-economic consequences.
      Despite attempts to prevent the complications of diabetes, this disease is still the leading
      cause of blindness, chronic renal insufficiency and non-traumatic amputation. It is important
      to detect early on an increase in blood sugar and treat it accordingly to reduce costs and to
      minimize the personal suffering of those affected. As the number of patients with type 2
      diabetes mellitus continues to rise, the number of young women with gestational diabetes
      mellitus (GDM) also increases. This is a disorder og glucose metabolism, which occurs for the
      first time in pregnancy. The causes for this are manifold. Among other causes, the increasing
      age of the mothers and weight gain during pregnancy are risk factors for gestational
      diabetes. Although it has been recommended that women with gestational diabetes should be
      re-examined after the birth of their child, many women have not. The study is a follow-up
      study to clarify whether insulin secretion disorder in women with and after GDM is a risk
      factor for the occurrence of type 2 diabetes mellitus.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 23, 2012</start_date>
  <completion_date type="Anticipated">May 1, 2028</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2027</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose tolerance during 75 g oral glucose tolerance test</measure>
    <time_frame>Glycemia from start of glucose tolerance test (0 minutes) until the end (120 minutes)</time_frame>
    <description>Glucose tolerance, insulin sensitivity and insulin secretion during oral glucose tolerance test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose tolerance during 75 g oral glucose tolerance test 1, 2, 5, 10 years postpartum</measure>
    <time_frame>Glycemia from start of glucose tolerance test (0 minutes) until the end (120 minutes)</time_frame>
    <description>Glucose tolerance during oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body fat distribution</measure>
    <time_frame>Once during pregnancy and 1, 2, 5, and 10 years postpartum</time_frame>
    <description>Measurement of body fat distribution by MRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spiroergometry to assess physical fitness</measure>
    <time_frame>1, 2, 5, and 10 years postpartum</time_frame>
    <description>Measurement of VO2max (l/min/kg) as a proxy for physical fitness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BIA (bioimpedance analysis)</measure>
    <time_frame>Once during pregnancy and 1, 2, 5, and 10 years postpartum</time_frame>
    <description>BIA to estimate body fat (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI</measure>
    <time_frame>Once during pregnancy and 1, 2, 5, and 10 years postpartum</time_frame>
    <description>Measurement of weight (kg) and height (m) and given as kg/m^2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of cognitive abilities in offspring</measure>
    <time_frame>6 and 10 years postpartum</time_frame>
    <description>Cognitive skills represented as an intelligence quotient will be assessed Wechsler Intelligence Scale for Children - Fifth Edition (WISC-V)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of cognitive, motoric and language development in offspring</measure>
    <time_frame>2 years postpartum</time_frame>
    <description>Cognitive, motoric and language development of children will be assessed with the Bayley Scales of Infant and Toddler Development - Third Edition (Bayley-III)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BIA in offspring</measure>
    <time_frame>2, 6 and 10 years postpartum</time_frame>
    <description>BIA to estimate body composition in offspring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram</measure>
    <time_frame>2, 6 and 10 years postpartum</time_frame>
    <description>10 minute ECG to assess RR distance for calculation of heart rate variability (R wave distance in ms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood sample</measure>
    <time_frame>6 and 10 years postpartum</time_frame>
    <description>blood sample to assess HbA1C</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Gestational Diabetes</condition>
  <arm_group>
    <arm_group_label>Women with GDM</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Women without GDM</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women in gestational week 24+0 till 31+6 and women postpartum who had a documented
        occurence of GDM in previous pregnancy.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Signed and dated informed consent

        Enrollment is possible during AND after gestation:

          -  Baseline visit (pregnancy): gestational week 24+0 till 31+6

          -  Postpartum visits: documented occurence of GDM in previous pregnancy

        Exclusion Criteria:

          -  Age &lt; 18years

          -  Diabetes Mellitus Type 1 or Type 2

          -  GFR &lt; 60 ml/min/1,73 m2

          -  CRP &gt; 1 mg/dl

          -  Increased levels of transaminases 2 fold above ULN

          -  Preexisting cardiac conditions

          -  Weight loss &gt; 10% within 6 months prior to inclusion

          -  Psychiatric disorders

          -  Chronic alcohol or substance abuse

          -  Blood sugar increasing or decreasing drug therapy, e.g. steroids, antidiabetics,
             insulin

          -  only postpartum visits: pregnancy or lactation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Fritsche, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Tuebingen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andreas Fritsche, MD</last_name>
    <phone>+49 7071 29</phone>
    <phone_ext>82711</phone_ext>
    <email>andreas.fritsche@med.uni-tuebingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Louise Fritsche, PhD</last_name>
    <phone>+49 7071 29</phone>
    <phone_ext>82711</phone_ext>
    <email>louise.fritsche@med.uni-tuebingen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Fritsche, MD</last_name>
      <phone>+49 7071 29</phone>
      <phone_ext>82711</phone_ext>
      <email>andreas.fritsche@med.uni-tuebingen.de</email>
    </contact>
    <contact_backup>
      <last_name>Louise Fritsche, PhD</last_name>
      <phone>+49 7071 29</phone>
      <phone_ext>82711</phone_ext>
      <email>louise.fritsche@med.uni-tuebingen.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 15, 2019</study_first_submitted>
  <study_first_submitted_qc>February 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2020</study_first_posted>
  <last_update_submitted>February 12, 2020</last_update_submitted>
  <last_update_submitted_qc>February 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gestational diabetes</keyword>
  <keyword>insulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes, Gestational</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

